Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting evolving market perceptions and sector dynamics. Despite a recent dip in share price, the company’s valuation metrics relative to peers and historical averages suggest a compelling investment proposition within the Pharmaceuticals & Biotechnology sector.

Glenmark Pharmaceuticals Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 31 January 2026. While the rating was revised on this date, the analysis and financial metrics discussed here reflect the company’s current position as of 31 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Glenmark Pharmaceuticals Ltd. posted a consolidated net profit of ₹403.21 crores for Q3 FY26, marking a robust 15.88% year-on-year growth but a sharp 33.94% sequential decline from the exceptional Q2 FY26 performance. The mid-cap pharmaceutical company, with a market capitalisation of ₹56,181 crores, demonstrated resilience in annual comparisons whilst navigating quarter-on-quarter volatility that characterised the nine-month period. The stock traded at ₹2,021.00 as of January 30, 2026, reflecting investor confidence despite the sequential moderation in earnings momentum.

Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, reflecting heightened market participation and a possible directional shift in investor sentiment. The stock’s recent outperformance against its sector and the broader Sensex, combined with rising volumes and delivery statistics, suggests growing confidence among traders and investors in the pharmaceutical giant’s near-term prospects.

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, reflecting heightened market participation and a potential shift in investor sentiment towards a bullish stance. The stock outperformed its sector peers and the broader Sensex, supported by increased volumes and rising delivery-based investor activity, signalling renewed confidence in the mid-cap pharmaceutical player.

Glenmark Pharmaceuticals Ltd. has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from a bullish to a mildly bullish trend. Despite a slight dip in daily price, the stock’s longer-term technicals and fundamental strength continue to support a positive outlook, underscored by an upgraded MarketsMOJO grade to Strong Buy.

Glenmark Pharmaceuticals Ltd. has witnessed a significant 18.25% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest price decline of 1.12% on 23 Jan 2026, the surge in open interest and volume suggests evolving directional bets amid mixed technical signals.

Glenmark Pharmaceuticals Ltd. has witnessed a notable 16.2% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest price decline of 0.73% on 23 Jan 2026, the surge in open interest and volume suggests evolving directional bets amid a backdrop of mixed technical signals and rising investor participation.

Glenmark Pharmaceuticals Ltd. has witnessed a significant 13.3% rise in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning despite a modest price decline. This surge in open interest, coupled with increased delivery volumes and mixed technical indicators, suggests evolving directional bets on the mid-cap pharmaceutical stock.

Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential shifts in investor positioning. Despite a marginal decline in the stock price, the underlying volume and open interest data suggest evolving directional bets among traders in the pharmaceuticals sector.

Glenmark Pharmaceuticals Ltd. has demonstrated a notable shift in technical momentum, with key indicators signalling a transition from mildly bullish to a more confident bullish stance. This change is underscored by robust moving averages, positive MACD trends, and supportive volume metrics, suggesting renewed investor interest and potential upside in the near term.

Glenmark Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a strongly bullish stance to a more cautious mildly bullish outlook. Despite a recent dip in price, the stock’s long-term fundamentals and technical grades suggest potential for recovery and sustained growth.

Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 18 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Glenmark Pharmaceuticals Ltd. is rated 'Strong Buy' by MarketsMOJO, with this rating last updated on 18 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 09 January 2026, providing investors with the most up-to-date view of the company's fundamentals, returns, and market standing.